

Luigi F Meneghini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9354720/publications.pdf>

Version: 2024-02-01

103
papers

2,391
citations

186265
28
h-index

223800
46
g-index

106
all docs

106
docs citations

106
times ranked

1990
citing authors

#	ARTICLE	IF	CITATIONS
1	Type 2 Diabetes and HbA1c Predict All-Cause Post-Metabolic and Bariatric Surgery Hospital Readmission. Obesity, 2021, 29, 71-78.	3.0	4
2	Optimizing Glucose Meter Downloads at Parkland Diabetes Clinic. Clinical Diabetes, 2021, 39, 199-202.	2.2	1
3	Lower-Extremity Amputation Trends Among People With Diabetes in a Large Urban Environment. Diabetes Care, 2021, 44, e91-e92.	8.6	6
4	Target attainment in insulin-naïve patients at high risk for hypoglycemia: Results from ACHIEVE Control. Journal of Diabetes and Its Complications, 2021, 35, 107831.	2.3	3
5	Decolonizing Care at Diagnosis: Culture, History, and Family at an Urban Intertribal Clinic. Medical Anthropology Quarterly, 2021, 35, 364-385.	1.4	1
6	Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2137-2154.	4.4	47
7	Daniel H. Mintz (1930-2020): An Extraordinary Physician-Scientist and a Pioneer in Islet Transplantation. Diabetes Care, 2021, 44, 1727-1733.	8.6	0
8	Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabetic Medicine, 2020, 37, 267-276.	2.3	6
9	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clinical Diabetes, 2020, 38, 371-381.	2.2	49
10	A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. Diabetes, Obesity and Metabolism, 2020, 22, 2004-2012.	4.4	11
11	Physician survey on pre/postprocedure measures for injectable treatments. Journal of Cosmetic Dermatology, 2020, 19, 2246-2251.	1.6	1
12	Design and Implementation of an Electronic Tool to Measure Medication Adherence at the Point of Care. Clinical Diabetes, 2020, 38, 382-385.	2.2	1
13	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care, 2020, 43, 2847-2852.	8.6	9
14	Cover Image, Volume 22, Issue 11. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
15	Multilevel Variation in Diabetes Screening Within an Integrated Health System. Diabetes Care, 2020, 43, 1016-1024.	8.6	6
16	Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 1995-2003.	4.4	10
17	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in Therapy, 2019, 36, 2310-2326.	2.9	2
18	Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 U/mL versus other basal insulin in a real-world setting. Endocrinology, Diabetes and Metabolism, 2019, 2, e00073.	2.4	6

#	ARTICLE	IF	CITATIONS
19	A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. Diabetes, Obesity and Metabolism, 2019, 21, 2133-2141.	4.4	5
20	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. Diabetes Therapy, 2019, 10, 617-633.	2.5	50
21	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1429-1436.	4.4	28
22	Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes. Diabetes Spectrum, 2019, 32, 303-311.	1.0	5
23	Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. Current Medical Research and Opinion, 2019, 35, 525-533.	1.9	4
24	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. Diabetes, Obesity and Metabolism, 2019, 21, 321-329.	4.4	15
25	Diabetic Skin Changes Can Benefit from Moisturizer and Cleanser Use: A Review. Journal of Drugs in Dermatology, 2019, 18, 1211-1217.	0.8	4
26	Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. Diabetes, Obesity and Metabolism, 2018, 20, 1298-1301.	4.4	6
27	Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. Diabetes, Obesity and Metabolism, 2018, 20, 1156-1165.	4.4	13
28	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy, 2018, 9, 1347-1358.	2.5	47
29	Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database. Diabetes, Obesity and Metabolism, 2018, 20, 831-839.	4.4	14
30	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy, 2018, 9, 2043-2053.	2.5	6
31	More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. Diabetes, Obesity and Metabolism, 2018, 20, 2314-2318.	4.4	14
32	Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study. Diabetes, 2018, 67, 1037-P.	0.6	1
33	Implementation of a Perioperative Insulin Protocol in an Advanced Practice Provider (APP)-Led Limb Salvage Hospitalist Team. Diabetes, 2018, 67, .	0.6	0
34	Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program. Diabetes, 2018, 67, .	0.6	0
35	Does Improving Glycemic Control Accelerate Healing of Diabetic Foot Ulcers?. Diabetes, 2018, 67, .	0.6	2
36	Diabetes Foot Wound Healing—A Collaborative Approach. Diabetes, 2018, 67, 645-P.	0.6	0

37	Diabetes Inside€”Following the Long-Term Impact of a Diabetes Quality Improvement (QI) Initiative in Primary Care. Diabetes, 2018, 67, 7-OR.	0.6	1
38	Role of Devices in Insulin Delivery. Diabetes Technology and Therapeutics, 2017, 19, 76-78.	4.4	4
39	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	4.4	100
40	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. Diabetes Technology and Therapeutics, 2017, 19, 315-322.	4.4	3
41	Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Postgraduate Medicine, 2016, 128, 731-739.	2.0	14
42	New insulin preparations: A primer for the clinician. Cleveland Clinic Journal of Medicine, 2016, 83, S27-S33.	1.3	9
43	Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. Diabetes/Metabolism Research and Reviews, 2015, 31, 537-544.	4.0	16
44	Clinical use of insulin degludec. Diabetes Research and Clinical Practice, 2015, 109, 19-31.	2.8	56
45	Metabolic Disturbances and the Intestinal Microbiome. US Endocrinology, 2015, 11, 34.	0.3	0
46	Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice (abstract). 18th Annual Meeting of the American Diabetes Association, 2014, 1, 101-P.	1.8	6
47	Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities. Patient, 2014, 7, 437-450.	2.7	60
48	Stepwise addition of prandial insulin. Lancet Diabetes and Endocrinology, 2014, 2, 3-4.	11.4	3
49	Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences. Endocrine Practice, 2014, 20, 75-83.	2.1	66
50	Maximal Sprint Does Not Alter Exercise Hemodynamics or Fuel Use in Individuals with Type-1 Diabetes. Medicine and Science in Sports and Exercise, 2014, 46, 157.	0.4	0
51	Maximal Sprints Prevent Hypoglycemia During Exercise and not Recovery in Individuals with Type 1 Diabetes. Medicine and Science in Sports and Exercise, 2014, 46, 546.	0.4	9
52	Insulin therapy for type 2 diabetes. Endocrine, 2013, 43, 529-534.	2.3	11
53	The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. Diabetes Care, 2013, 36, 858-864.	8.6	214

#	ARTICLE	IF	CITATIONS
55	Lower Within-Subject Variability in Mean Blood Glucose Concentration with Insulin Degludec vs. Insulin Glargine: A Meta-Analysis of Patients with Type 2 Diabetes. Canadian Journal of Diabetes, 2013, 37, S26.	0.8	0
56	Screening, evaluation and management of depression in people with diabetes in primary care. Primary Care Diabetes, 2013, 7, 1-10.	1.8	91
57	Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes. Primary Care Diabetes, 2013, 7, 85.	1.8	1
58	Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI ≥ 30 kg/m ² : A Meta-analysis of 5 Randomized Trials. Canadian Journal of Diabetes, 2013, 37, S56.	0.8	0
59	Insulin degludec improves health-related quality of life (SF-36 [®]) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabetic Medicine, 2013, 30, 226-232.	2.3	32
60	Bariatric intervention effective at reversing Type 2 diabetes. Evidence-Based Medicine, 2013, 18, 68-69.	0.6	0
61	Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. Endocrine Practice, 2013, 19, 718-728.	2.1	9
62	Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treatment-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 729-736.	4.4	55
63	Effect of Baseline Glycosylated Hemoglobin A1C on Glycemic Control and Diabetes Management following Initiation of Once-daily Insulin Detemir in Real-Life Clinical Practice. Endocrine Practice, 2013, 19, 462-470.	2.1	17
64	Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. Expert Review of Endocrinology and Metabolism, 2012, 7, 9-14.	2.4	13
65	Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-analysis of T1DM and T2DM. Canadian Journal of Diabetes, 2012, 36, S47.	0.8	0
66	Less Nocturnal Hypoglycemia for Insulin Degludec vs. Insulin Glargine in Subjects with T1DM and Baseline A1c of 7.5%–8.5%: A Meta-Analysis. Canadian Journal of Diabetes, 2012, 36, S46.	0.8	0
67	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes/Metabolism Research and Reviews, 2012, 28, 258-267.	4.0	15
68	Study of Once Daily Levemir (SOLVE [®]): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes, Obesity and Metabolism, 2012, 14, 654-661.	4.4	99
69	Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabetic Medicine, 2012, 29, 716-720.	2.3	31
70	Individualizing insulin therapy. Journal of Family Practice, 2012, 61, S13-27.	0.2	1
71	Comparison of 2 Intensification Regimens with Rapid-Acting Insulin Aspart in Type 2 Diabetes Mellitus Inadequately Controlled by Once-Daily Insulin Detemir and Oral Antidiabetes Drugs: The Step-Wise Randomized Study. Endocrine Practice, 2011, 17, 727-736.	2.1	63
72	Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clinical Immunology, 2011, 139, 290-301.	3.2	35

#	ARTICLE	IF	CITATIONS
73	Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011, 34, 661-665.	8.6	156
74	Insulin for intensifying diabetes treatment. <i>Journal of Family Practice</i> , 2011, 60, S21-8.	0.2	0
75	Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2010, 16, 588-599.	2.1	29
76	Practical Aspects and Considerations When Switching Between Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, S-109-S-114.	4.4	11
77	Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes. <i>American Journal of Nephrology</i> , 2010, 31, 110-116.	3.1	17
78	Letter to the editor Insulin - Volume 5, Issue 1. <i>Insulin</i> , 2010, 5, 63-65.	0.2	0
79	Introduction. <i>Primary Care Diabetes</i> , 2010, 4, S1-S2.	1.8	1
80	Insulin detemir: A historical perspective on a modern basal insulin analogue. <i>Primary Care Diabetes</i> , 2010, 4, S31-S42.	1.8	19
81	Practical guidance to insulin management. <i>Primary Care Diabetes</i> , 2010, 4, S43-S56.	1.8	14
82	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2010, 10, 23.	1.5	11
83	Early Insulin Treatment in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, S266-S269.	8.6	40
84	Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. <i>Advances in Therapy</i> , 2009, 26, 194-207.	2.9	7
85	Perioperative management of diabetes: Translating evidence into practice. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S53-S59.	1.3	46
86	Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study. <i>International Journal of Clinical Practice</i> , 2008, 62, 659-665.	1.7	65
87	Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. <i>International Journal of Clinical Practice</i> , 2008, 62, 1255-1264.	1.7	15
88	Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. <i>Current Medical Research and Opinion</i> , 2008, 24, 11-20.	1.9	36
89	Clarification of the Similarities and Differences Among Insulin Analog Preparations: Response to Becker. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, 51-53.	4.4	8
90	Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 513-529.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Superior Mesenteric Artery Syndrome in Type 1 Diabetes Masquerading as Gastroparesis. Diabetes Care, 2008, 31, 1983-1984.	8.6	15
92	Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Medical Research and Opinion, 2008, 24, 11-20.	1.9	23
93	Continued Use of an Integrated Meter with Electronic Logbook Maintains Improvements in Glycemic Control Beyond a Randomized, Controlled Trial. Diabetes Technology and Therapeutics, 2007, 9, 254-264.	4.4	19
94	The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE 303 study. Diabetes, Obesity and Metabolism, 2007, 9, 902-913.	4.4	116
95	Why and How to Use Insulin Therapy Earlier in the Management of Type 2 Diabetes. Southern Medical Journal, 2007, 100, 164-174.	0.7	19
96	Appropriate advancement of type 2 diabetes therapy. Journal of Family Practice, 2007, 56, 19A-29A; quiz 30A.	0.2	0
97	Pharmacotherapies for Diabetes Management: An Update for the Practicing Clinician. Seminars in Thoracic and Cardiovascular Surgery, 2006, 18, 379-389.	0.6	3
98	Prevalence and Associations of Binge Eating Disorder in a Multiethnic Population With Type 2 Diabetes. Diabetes Care, 2006, 29, 2760-2760.	8.6	59
99	Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2005, 7, 88-97.	4.4	66
100	Evaluation of Metabolic Control Using a Continuous Subcutaneous Glucose Monitoring System in Patients with Type 1 Diabetes Mellitus who Achieved Insulin Independence after Islet Cell Transplantation. Cell Transplantation, 2005, 14, 77-84.	2.5	33
101	How Good Is Your Glucose Control?. Diabetes Technology and Therapeutics, 2005, 7, 863-875.	4.4	8
102	Obesity, bariatric surgery and type 2 diabetes? a systematic review. Diabetes/Metabolism Research and Reviews, 2004, 20, 438-445.	4.0	80
103	Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics, 2004, 26, 379-389.	2.5	35